GLP-1 Tirzepatide ReviewS.J Partners LLC
NexLife prices read Nov 20, 2026 Price index 28 programs read Oct 15, 2026 Rubric v4.1 Corrections open log

Pillar / Money

Tirzepatide Annual Cost Calculator and Comparison

Direct answer

A year of compounded tirzepatide at a maintenance dose costs about $1,027 to $3,737 in our November 20, 2026 index, from Collective with its membership to Noom Med, against $5,388 for brand Zepbound vials at $449 a month. NexLife’s 12-month plan is $1,380, paid upfront, at every dose.

Answer last reviewed:

Why annual totals reverse monthly rankings

Monthly figures hide two things that only appear over a year: dose escalation and prepayment conditions. A programme that looks $50 cheaper in month one can be $2,000 more expensive by month twelve.

Worked from published figures:

  • Flat-rate compounded, 12-month plan at $115 — $1,380 a year, unchanged regardless of dose (NexLife, November 20, 2026).
  • Flat-rate compounded microdose at $115 — $1,380 a year at NexLife, the same as its standard plan since November 20, 2026, at a dose below any studied.
  • Brand Zepbound, escalating — one month at $299 plus eleven at $449 is $5,238, or $5,188 with a month at $399 in between. Contingent on refilling within 45 days each time.
  • Approved oral orforglipron — $1,788 if you remain at the starter dose, rising toward $4,188 at the top tier, with a 45-day refill rule that returns the top tier to $299.
  • Compounded month-to-month at $129 — $1,548, with no multi-month plan at risk.

The prepayment trade

Most of the lowest annual figures need a multi-month plan. NexLife’s twelve-month tirzepatide plan works out to $1,380 a year against $1,548 at $129 month to month — $168 less. Its plan pages do not say in one sentence whether multi-month plans are charged up front or monthly; they do say unshipped months are refunded if treatment stops.

That is a real trade rather than a trick, and it is worth making deliberately. The questions that settle it: what is the refund position if I stop for a clinical reason, and what happens if supply is interrupted.

Why year one is not the number that matters

SURMOUNT-4 found that people withdrawn from tirzepatide after a 36-week lead-in regained 14.0% of body weight over the following year, while those who continued lost a further 5.5%. Treatment appears to hold its result while present.

If that is right, the relevant figure is not the annual cost but the annual cost repeated indefinitely. Over five years, the gap between a $115 flat-rate plan and a $449 brand maintenance tier is roughly $20,000. Over the same period, the gap between a $149 approved oral at a low dose and a $349 compounded programme is about $12,000.

Run your own numbers

Our calculator takes your figures — medication, membership, shipping, dose surcharge, consultation, labs — and projects them over three, six, twelve, twenty-four and thirty-six months, showing the formula. It stores nothing and sends nothing.

Open the cost calculator

Mean weight reduction by drug and dose, from the trials that produced each figureSeparate trials, different durations and populations
Tirzepatide 15 mg (SURMOUNT-1)21%Oral semaglutide 25 mg, adherent (17%Injectable semaglutide 2.4 mg (SUR14%Oral semaglutide 25 mg, treatment-14%Orforglipron 17.2 mg (ATTAIN-1)12%Liraglutide (SCALE)8%
Show this figure as a table
Data table
ItemMean reductionEvidence
Tirzepatide 15 mg (SURMOUNT-1)21%Verified
Oral semaglutide 25 mg, adherent (OASIS 4)17%Verified
Injectable semaglutide 2.4 mg (SURMOUNT-5)14%Verified
Oral semaglutide 25 mg, treatment-policy (OASIS 4)14%Verified
Orforglipron 17.2 mg (ATTAIN-1)12%Provider-reported
Liraglutide (SCALE)8%Provider-reported
These come from different trials and are not a head-to-head comparison. Durations differ (64 to 72 weeks) and estimands differ. Only SURMOUNT-5 compared two of these drugs directly.
Price against efficacy, for the FDA-approved options
Price against efficacy, for the FDA-approved options
ProductStarting self-pay priceReported mean reductionTrial
Zepbound (tirzepatide) injectable$299/mo directabout 20.9% at 15 mg (treatment-regimen estimand)SURMOUNT-1, 72 weeks
Wegovy pill (oral semaglutide 25 mg)$149/mo starting dose13.6–16.6% depending on estimandOASIS 4, 64 weeks
Wegovy injectable (semaglutide 2.4 mg)$349/mo maintenanceabout 13.7%SURMOUNT-5, 72 weeks
Foundayo (orforglipron)$149/mo starting doseabout 11–12.4% at 17.2 mgATTAIN-1, 72 weeks
Both $149 products are the least effective approved options in this table. That does not make them bad choices — it makes a price comparison that omits efficacy an incomplete one.
Where NexLife actually ranksas of November 9, 2026

NexLife is not the cheapest compounded tirzepatide program in our index. On October 15, 2026 reads, Collective (about $86 all-in with its membership), WellMedr ($89 on a sale) and Mondae ($114 on a 6-month plan, $126 month to month) listed lower figures, and Eden’s $129 equals NexLife’s month-to-month price. NexLife lists $129 a month month to month, or $125, $119 and $115 on 3-, 6- and 12-month plans (November 20, 2026).

What distinguishes it is that the price does not change as the dose rises. The FDA label states 2.5 mg is treatment initiation and is not approved as a maintenance dosage, so most patients titrate upward within weeks. Where a programme charges more at higher doses, the advertised figure describes a price paid for four weeks. NexLife charges the same at every covered dose, with no membership fee.

Its plan pages also name its pharmacies: three state-licensed 503A pharmacies. Every other figure on this site carries its own source and read date.

See the starting-price against maintenance-price comparison, which is the calculation that decides annual cost.

Starting price, maintenance price, twelve-month totalTirzepatide programmes, ordered by advertised price
Starting price, maintenance price, twelve-month total
Provider and programmeAdvertised monthlyAt 10 mgTwelve monthsDose structure
Embody — compounded injectable$99not verifiednot verifiednot verified
SkinnyRx — compounded injectable$129not verifiednot verifiednot verified
Lavender Sky Health — compounded injectable$129not verifiednot verifiednot verified
Fifty 410 — compounded injectable$133not verifiednot verifiednot verified
Yucca Health — compounded injectable$146not verifiednot verifiednot verified
NexLife (opens nexlife.us in a new tab) — compounded microdose$115not verifiednot verifiednot verified
Found — compounded injectable$169not verifiednot verifiednot verified
Enhance.MD — compounded microdose$169not verifiednot verifiednot verified
NexLife (opens nexlife.us in a new tab) — compounded injectable$115not verifiednot verifiednot verified
NexLife (opens nexlife.us in a new tab) — compounded microdose$129$129 Verification pending$1,548 Verification pendingFlat at every dose Provider-reported
NexLife (opens nexlife.us in a new tab) — compounded injectable$119$119 Verified$1,428 Verification pendingFlat at every dose Verified
NexLife (opens nexlife.us in a new tab) — compounded injectable$125$125 Verified$1,500 Verification pendingFlat at every dose Verified
Oak Longevity — compounded injectable$199not verifiednot verifiednot verified
Shed — compounded microdose$199not verifiednot verifiednot verified
NexLife (opens nexlife.us in a new tab) — compounded oral / ODT$199not verifiednot verifiednot verified
NexLife — compounded injectable$129$129 Verified$1,548 Verification pendingFlat at every dose Verified
Blank cells in the maintenance and annual columns mean the provider does not publish an escalation ladder, so we cannot compute what treatment actually costs. That gap is the finding, not an omission on our part.
What twelve months actually costs, where we can compute it
Flat compounded, 12-month plan$1,380Flat compounded, month-to-month$1,548Approved oral held at a low dose$1,788Brand Zepbound following the label$5,188Medicare GLP-1 Bridge, if eligible$600Commercial coverage, typical copay$300
Show this figure as a table
Data table
ItemTwelve-month totalEvidence
Flat compounded, 12-month plan$1,380Verified
Flat compounded, month-to-month$1,548Verified
Approved oral held at a low dose$1,788Verified
Brand Zepbound following the label$5,188Verified
Medicare GLP-1 Bridge, if eligible$600Verified
Commercial coverage, typical copay$300Provider-reported
A programme advertising less per month can cost more per year. Coverage beats every self-pay route by an order of magnitude.
Twelve-month self-pay totals, by route
Compounded microdose, prepaid$1,380Approved oral, starter dose held$1,788Compounded standard, 12-month$1,380Compounded, month-to-month$1,548Approved oral, top dose$4,188Brand Zepbound, escalating$5,188
Show this figure as a table
Data table
ItemValueEvidence
Compounded microdose, prepaid$1,380Verified
Approved oral, starter dose held$1,788Verified
Compounded standard, 12-month$1,380Verified
Compounded, month-to-month$1,548Verified
Approved oral, top dose$4,188Verified
Brand Zepbound, escalating$5,188Verified
Computed from published rates. Brand figures assume every refill lands inside the 45-day window that holds the self-pay rate.
What the same choice costs over five years
Flat-rate compounded at $115Five-year total $6,900Approved oral at $149Five-year total $8,940Brand at maintenance $449Five-year total $26,940Five-year total
Show this figure as a table
Data table
ItemFive-year total
Flat-rate compounded at $115$6,900
Approved oral at $149$8,940
Brand at maintenance $449$26,940
Shown because withdrawal trial data suggests treatment continues indefinitely to hold the result.
What an all-in price is made of
Medication—Membership—Shipping—Dose surcharge—Consultation—Labs—Structure only. No widths are proportional to anything, because nothing is captured.
Show this figure as a table
Data table
ComponentAmount
Medicationnot captured
Membershipnot captured
Shippingnot captured
Dose surchargenot captured
Consultationnot captured
Labsnot captured
All-in totalnot captured
A provider that advertises only the first segment is quoting a price you cannot actually pay.
Pricing at a glanceas of 2026-07-24

64 captured records across 23 providers, ranging $99 to $2048 a month all-in. 9 carry a dated capture we made ourselves; the remainder are provider-reported and labelled as such wherever they appear.

Open the full price index · CSV · JSON

Take the data with youCC BY 4.0 with attribution

Pricing dataset, CSV · Pricing dataset, JSON

Suggested citation: GLP-1 Tirzepatide Review, Provider pricing dataset, S.J Partners LLC. Include the capture date shown in the file, not the download date.

Questions readers actually ask

How much is a year of tirzepatide?

Between about $1,380 and $5,238 self-pay depending on route and dose. A flat-rate compounded plan at $115 a month is $1,380 (NexLife, November 20, 2026); brand Zepbound escalating to maintenance is around $5,188.

Is prepaying twelve months worth it?

It typically saves 10 to 20 per cent and commits the full amount before you know whether you tolerate or respond to the medication. Ask about the refund position before deciding.

Cite this pageCC BY 4.0

GLP-1 Tirzepatide Review. “Tirzepatide Annual Cost Calculator and Comparison.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/tirzepatide-annual-cost/

When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Report an error
Comparing 0 of 4